IHL INCANNEX HEALTHCARE LTD

EQS-News: Incannex kicks off manufacture of skin therapeutics

EQS-News: Incannex Healthcare Ltd
Incannex kicks off manufacture of skin therapeutics

29.11.2022 / 21:20 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive Investors

Jonathan Jackson


News Source: News Direct

29.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Incannex Healthcare Ltd
United States
ISIN: AU000000IHL8
EQS News ID: 1501123

 
End of News EQS News Service

1501123  29.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1501123&application_name=news&site_id=research_pool
EN
29/11/2022

Underlying

IHLINCANNEX HEALTHCARE LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INCANNEX HEALTHCARE LTD

 PRESS RELEASE
Free
IHL INCANNEX HEALTH...

EQS-News: Incannex Healthcare discusses A$13 million institutional pla...

EQS-News: Incannex Healthcare Ltd Incannex Healthcare discusses A$13 million institutional placement 06.12.2022 / 20:00 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactive InvestorsJonathan Jackson News Source: News Direct 06.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive...

December 6, 2022 1 EN
 PRESS RELEASE
Free
IHL INCANNEX HEALTH...

EQS-News: Incannex kicks off manufacture of skin therapeutics

EQS-News: Incannex Healthcare Ltd Incannex kicks off manufacture of skin therapeutics 29.11.2022 / 21:20 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactive InvestorsJonathan Jackson News Source: News Direct 29.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at -news.com Languag...

November 29, 2022 1 EN
 PRESS RELEASE
Free
IHL INCANNEX HEALTH...

Incannex Healthcare (IXHL): Initiation — Addressing unmet needs via un...

Edison Investment Research Limited Incannex Healthcare (IXHL): Initiation — Addressing unmet needs via unique approach 30-Aug-2022 / 12:38 GMT/BST   London, UK, 30 August 2022   Incannex Healthcare (IXHL): Initiation — Addressing unmet needs via unique approach Incannex Healthcare is an Australian biotech specializing in the development of treatments for chronic conditions through a unique approach. Specifically, the company is investigating the use of cannabinoids and psychedelics, leveraging its synergistic combination intellectual property. Most recently, it has achieved proo...

August 30, 2022 1 EN
Sean Conroy
  • Sean Conroy
IHL INCANNEX HEALTH...

Incannex Healthcare - Addressing unmet needs via alternative approach

Incannex Healthcare is an Australian biotech specializing in the development of treatments for chronic conditions through a unique approach. Specifically, the company is investigating the use of cannabinoids and psychedelics, leveraging its synergistic combination intellectual property (IP). Most recently, it has achieved proof-of-concept in Australia for IHL-42X, its lead asset for the treatment of obstructive sleep apnea (OSA). The company intends to file an investigational new drug applicatio...

IHL INCANNEX HEALTHCARE LTD
08/30/22 August 30, 2022 1 EN
Sean Conroy
  • Sean Conroy
IHL INCANNEX HEALTH...

Incannex Healthcare - APIRx acquisition to bolster portfolio

Incannex Healthcare, an Australian cannabinoid and psychedelic medicines biotech, has announced that it has completed the acquisition of APIRx Pharmaceuticals (APIRx), a US biotechnology company focused on the development and manufacture of cannabinoid formulations. In an all-share transaction, Incannex has acquired 100% of the issued share capital in APIRx. APIRx’s pipeline consists of 22 clinical and pre-clinical therapeutic cannabinoid development programmes and an extensive intellectual prop...

IHL INCANNEX HEALTHCARE LTD
08/08/22 August 8, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch